The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
Herthena-Lung02 data are an ASCO shocker.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
